601 reports of this reaction
2.1% of all BRIMONIDINE TARTRATE reports
#10 most reported adverse reaction
INTRAOCULAR PRESSURE INCREASED is the #10 most commonly reported adverse reaction for BRIMONIDINE TARTRATE, manufactured by Sandoz Inc. There are 601 FDA adverse event reports linking BRIMONIDINE TARTRATE to INTRAOCULAR PRESSURE INCREASED. This represents approximately 2.1% of all 28,834 adverse event reports for this drug.
Patients taking BRIMONIDINE TARTRATE who experience intraocular pressure increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INTRAOCULAR PRESSURE INCREASED is a less commonly reported adverse event for BRIMONIDINE TARTRATE, but still significant enough to appear in the safety profile.
In addition to intraocular pressure increased, the following adverse reactions have been reported for BRIMONIDINE TARTRATE:
The following drugs have also been linked to intraocular pressure increased in FDA adverse event reports:
INTRAOCULAR PRESSURE INCREASED has been reported as an adverse event in 601 FDA reports for BRIMONIDINE TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INTRAOCULAR PRESSURE INCREASED accounts for approximately 2.1% of all adverse event reports for BRIMONIDINE TARTRATE, making it a notable side effect.
If you experience intraocular pressure increased while taking BRIMONIDINE TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.